GLP-1 Medications and Kidney Health: What Seniors With CKD Need to Know

Why Kidney Health Matters When Starting a GLP-1

Chronic kidney disease (CKD) affects roughly 37 million American adults, and the prevalence rises sharply after age 60. According to the National Kidney Foundation, nearly one in three seniors over 65 has some degree of CKD — many without realizing it. If you are considering a GLP-1 medication like Wegovy (semaglutide) or Zepbound (tirzepatide) through Medicare, your kidney function is one of the first things your doctor will evaluate.

The good news: emerging research suggests GLP-1 medications may actually offer kidney-protective benefits. But the picture is nuanced, and seniors with advanced kidney disease need careful monitoring.

What the Research Shows About GLP-1 and Kidneys

A landmark 2024 study published in the New England Journal of Medicine — the FLOW trial — found that semaglutide reduced the risk of major kidney events by 24 percent in patients with Type 2 diabetes and chronic kidney disease. Lead researcher Vlado Perkovic, MBBS, PhD, of the University of New South Wales, called the results 'a major advance in kidney disease treatment.'

The study showed that semaglutide slowed the decline of estimated glomerular filtration rate (eGFR), reduced proteinuria (protein in the urine), and lowered the risk of kidney failure requiring dialysis. These findings led the American Diabetes Association to update its 2025 Standards of Care to recommend GLP-1 receptor agonists for patients with diabetic kidney disease.

For tirzepatide, the SURPASS-4 trial demonstrated similar kidney-protective signals, with significant reductions in urinary albumin-to-creatinine ratio over 52 weeks of treatment.

CKD Stages and GLP-1 Eligibility

Kidney function is measured by eGFR, which estimates how well your kidneys filter waste. Here is how CKD stages relate to GLP-1 medication use:

• Stage 1–2 (eGFR 60+): Generally safe to use GLP-1 medications at standard doses with routine monitoring
• Stage 3a (eGFR 45–59): Typically safe, but your doctor may start at a lower dose and monitor kidney labs more frequently
• Stage 3b (eGFR 30–44): Use with caution — dose adjustments may be needed, and dehydration risk must be carefully managed
• Stage 4 (eGFR 15–29): Limited data — your nephrologist and prescriber should collaborate closely on the decision
• Stage 5 (eGFR below 15 or dialysis): GLP-1 medications are generally not recommended due to insufficient safety data

The Dehydration Connection

The biggest kidney-related risk with GLP-1 medications is not from the drug itself — it is from dehydration. GLP-1 side effects like nausea, vomiting, and reduced appetite can lead seniors to drink less water and eat fewer hydrating foods. For someone with already-compromised kidneys, even mild dehydration can trigger acute kidney injury (AKI).

Dr. Katherine Tuttle, a nephrologist at Providence Medical Research Center, has emphasized that 'the renal safety signal with GLP-1 agonists is generally favorable, but volume depletion remains the primary concern, especially in older patients on diuretics.'

Medications That Increase Kidney Risk on GLP-1

Many seniors take medications that affect kidney function. Your doctor should review your full medication list before prescribing a GLP-1. Combinations that require extra monitoring include:

• Diuretics (furosemide, hydrochlorothiazide) — increase dehydration risk
• ACE inhibitors or ARBs (lisinopril, losartan) — can compound kidney stress during dehydration
• NSAIDs (ibuprofen, naproxen) — reduce blood flow to kidneys and should generally be avoided with CKD
• Metformin — dose may need adjustment based on eGFR changes

Monitoring Your Kidneys While on a GLP-1

If you have CKD and start a GLP-1 medication, expect more frequent lab work than someone with normal kidney function. The National Kidney Foundation recommends:

• Baseline labs before starting: eGFR, BUN, creatinine, urinalysis, and electrolytes
• Follow-up labs at 4 weeks, then every 3 months for the first year
• Urine albumin-to-creatinine ratio (UACR) every 6 months to track protein spillage
• Immediate labs if you experience vomiting, diarrhea, or signs of dehydration

What to Tell Your Doctor

Before your appointment, gather these key pieces of information to help your doctor make the best decision about GLP-1 therapy:

• Your most recent eGFR and creatinine results (ask your primary care doctor or nephrologist)
• A complete list of all medications, including over-the-counter drugs and supplements
• Your daily water intake and any history of kidney stones or urinary tract infections
• Whether you have ever been hospitalized for dehydration or acute kidney injury

Related Articles

• GLP-1 Side Effects Seniors Should Know Before Starting
• How to Stay Hydrated on a GLP-1 — Why It Matters More After 65
• GLP-1 Medications and Your Other Prescriptions: What Seniors Need to Know
• Medical Conditions That May Prevent You From Taking a GLP-1

Sources

• Perkovic V, et al. 'Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.' New England Journal of Medicine, 2024 (FLOW Trial)
• National Kidney Foundation. 'Chronic Kidney Disease in the United States, 2023.' kidney.org
• American Diabetes Association. 'Standards of Care in Diabetes — 2025.' Diabetes Care, 2025
• Tuttle KR. 'GLP-1 Receptor Agonists and Kidney Protection.' Providence Medical Research Center commentary, 2024
• Heerspink HJL, et al. 'SURPASS-4: Tirzepatide and Kidney Outcomes.' The Lancet Diabetes & Endocrinology, 2022